- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.03. | Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating | 1 | Investing.com | ||
| 11.03. | Artiva Biotherapeutics: Cantor Fitzgerald bekräftigt "Overweight"-Rating | 4 | Investing.com Deutsch | ||
| 10.03. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights | 646 | GlobeNewswire (Europe) | Initial clinical response data for AlloNK in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial... ► Artikel lesen | |
| 10.03. | Artiva Biotherapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 24.02. | Artiva Biotherapeutics Names Thad Huston CFO | 3 | RTTNews | ||
| 24.02. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant | 348 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible... ► Artikel lesen | |
| ARTIVA BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.02. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.01. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology ... | 1 | GlobeNewswire (USA) | ||
| 12.12.25 | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.11.25 | Artiva BioTherapeutics GAAP EPS of -$0.88 | 3 | Seeking Alpha | ||
| 12.11.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK in Autoimmune Disease | 280 | GlobeNewswire (Europe) | 32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were... ► Artikel lesen | |
| 12.11.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 233 | GlobeNewswire (Europe) | Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®... ► Artikel lesen | |
| 12.11.25 | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | Artiva Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update | 455 | GlobeNewswire (Europe) | Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate... ► Artikel lesen | |
| 13.05.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT ... | 241 | GlobeNewswire (Europe) | 64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL... ► Artikel lesen | |
| 08.05.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights | 419 | GlobeNewswire (Europe) | IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis ... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,20 | -1,43 % | BioNTech: Gute News - doch reicht das? | Nach dem heftigen Rücksetzer bei BioNTech, nachdem bekannt wurde, dass die beiden Gründer Ugur Sahin und Özlem Türeci bis spätestens Ende des Jahres das Unternehmen verlassen werden, arbeitet die Aktie... ► Artikel lesen | |
| AMGEN | 301,80 | -0,02 % | Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP | ||
| NOVAVAX | 7,370 | -1,86 % | Is Shah Capital's Criticism of Novavax Fair? A Wall Street Analyst Weighs In | ||
| BIOGEN | 152,00 | +0,88 % | Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks | ||
| VIKING THERAPEUTICS | 29,800 | -0,33 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| MAINZ BIOMED | 0,487 | 0,00 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 12,360 | -2,68 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 46,380 | -2,31 % | Here's What TD Cowen Thinks About Tempus AI Inc (TEM) Stock | ||
| BIOCRYST PHARMACEUTICALS | 8,100 | +0,40 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2026 Financial Results on May 6 | ||
| BIOMARIN PHARMACEUTICAL | 45,660 | 0,00 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,960 | -1,86 % | H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target | ||
| EXELIXIS | 38,160 | +0,03 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,409 | -1,61 % | PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing | ||
| CARDIOL THERAPEUTICS | 1,252 | -2,34 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.04.2026 / 15:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart announces $25M share purchase agreement |
ARTIVA BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 12,490 Euro und damit +3,14 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARTIVA BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.